Posts

The near year-long infant formula shortage in the United States that prompted the intervention of the White House is likely to “persist” until spring, according to Reckitt Benckiser, the maker of what is now the biggest brand in the market, Enfamil.

The partnership with non-profit IVI, headquartered in South Korea, aims to boost output and reduce vaccine shortages amid a spate of global outbreaks that spurred the World Health Organization to temporarily change its dosage regime.

The company cited Gavi’s failure to procure the 350 million doses it had agreed to buy in May last year for the COVAX facility.

The Southeast Asian country temporarily banned sales of some syrup-based medications in October after it identified the presence in some products of ethylene glycol and diethylene glycol as possible factors for causing the illness.

Moderna Inc cut its annual sales forecast for its COVID-19 vaccine, citing short-term supply constraints that would push some deliveries to next year, sending its shares down nearly 11% before the bell.

Indegene will leverage its healthcare domain expertise and experience in operating digital centers of excellence to help streamline AstraZeneca’s global content supply chain and orchestrate personalized customer journeys in an agile, global engagement model.

BMS said its third-quarter sales fell from last year as generic competition ate into sales of its blockbuster cancer drug Revlimid in the United States, as well as the effect of the weak euro and pound.

The company said its generic drugs division Sandoz would continue to provide medicines to all of its European markets because a surge in energy costs can be offset by efficiency measures.

Johnson & Johnson on Tuesday posted better than expected third-quarter earnings on strong demand for its cancer drug Darzalex, but said it may still cut some jobs as it contends with inflationary pressure and challenges created by the strong dollar.

Supply problems with the weight loss drug Wegovy were a stumbling block to growth, but Novo Nordisk has rallied.